Non-adherence to disease-modifying antirheumatic drugs is associated with higher disease activity in early arthritis patients in the first year of the disease

Table 2 Univariate and multivariate generalized linear mixed model for repeated data: determinants for DAS28 over the first year for rheumatoid arthritis patients over a 3-, 6-, 9- and 12-month period

	T1:				T1-2:				T1-2-3:				T1-2-3-4:
	3 months				3–6 months				3-6-9 months				3–6–9–12 months
	Univariate	p value	Multivariate	p value	Univariate	p value	Multivariate	p value	Univariate	p value	Multivariate	p value	Univariate	p value	Multivariate	p value
Intercept			2.02	<0.01			1.45	<0.01			1.57	<0.01			1.65	<0.01
Non-adherence	1.22	0.06	1.14	0.08	1.18	0.01	1.04	0.03	0.71	0.07	0.52	0.18	0.28	0.40	0.19	0.57
Weeks on DMARDs	−0.10	0.25	−0.08	0.10	−0.02	0.02	−0.02	<0.01	−0.02	<0.01	−0.02	<0.01	−0.01	<0.01	−0.01	<0.01
Baseline DAS28	0.36	<0.01	0.38	<0.01	0.35	<0.01	0.32	<0.01	0.32	<0.01	0.28	<0.01	0.30	<0.01	0.25	<0.01
Age (standardized)	0.01	0.17	0.001	0.92	0.02	0.07	0.01	0.29	0.02	0.03	0.01	0.11	0.02	0.03	0.01	0.11
Baseline anxiety	0.04	0.15	0.02	0.49	0.05	0.08	0.04	0.13	0.05	0.06	0.04	0.07	0.04	0.06	0.04	0.09
Education level	−0.17	0.63			−0.16	0.27			−0.16	0.23			−0.16	0.20
Biological use	^#				1.73	0.02	^#		0.09	0.83			−0.09	0.78
Subcutaneous MTX	0.38	0.51			0.43	0.23			0.32	0.24			0.16	0.51
Gender	0.22	0.39			0.19	0.44			0.14	0.53			0.08	0.72
Baseline depression	0.05	0.31			0.04	0.33			−0.03	0.43			0.02	0.62
ACPA/RF	−0.11	0.40			−0.04	0.73			−0.04	0.74			−0.002	0.98
Number of DMARDs	0.08	0.54			0.03	0.79			0.02	0.83			−0.02	0.84
Symptom duration >6 weeks	−0.07	0.84			0.04	0.92			0.05	0.88			0.03	0.92

DAS28 28-joint count disease activity score, DMARDs disease-modifying antirheumatic drugs, MTX methotrexate, ACPA anti-cyclic citrullinated peptide antibodies, RF rheumatoid factor
^#No/only one patient received biologicals at this time point

ISSN: 1478-6362